Tevogen Bio Holdings Inc.

Healthcare · Biotechnology · United States

Last price 5.9 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 92.85M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Tevogen Inc., a clinical-stage specialty immunotherapy company, develops off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and other disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment of ambulatory high-risk adult COVID-19 patients; and in Phase 1 clinical trial to treat acute SARS-CoV-2 patients with B-cell cancer immune suppression, and other B cell immune suppressed acute SARS-CoV-2 patients with a B cell cancer indication, as well as Long COVID pr...